» Articles » PMID: 17556660

Knock-in Mouse Model of Dilated Cardiomyopathy Caused by Troponin Mutation

Abstract

We created knock-in mice in which a deletion of 3 base pairs coding for K210 in cardiac troponin (cTn)T found in familial dilated cardiomyopathy patients was introduced into endogenous genes. Membrane-permeabilized cardiac muscle fibers from mutant mice showed significantly lower Ca(2+) sensitivity in force generation than those from wild-type mice. Peak amplitude of Ca(2+) transient in cardiomyocytes was increased in mutant mice, and maximum isometric force produced by intact cardiac muscle fibers of mutant mice was not significantly different from that of wild-type mice, suggesting that Ca(2+) transient was augmented to compensate for decreased myofilament Ca(2+) sensitivity. Nevertheless, mutant mice developed marked cardiac enlargement, heart failure, and frequent sudden death recapitulating the phenotypes of dilated cardiomyopathy patients, indicating that global functional defect of the heart attributable to decreased myofilament Ca(2+) sensitivity could not be fully compensated by only increasing the intracellular Ca(2+) transient. We found that a positive inotropic agent, pimobendan, which directly increases myofilament Ca(2+) sensitivity, had profound effects of preventing cardiac enlargement, heart failure, and sudden death. These results verify the hypothesis that Ca(2+) desensitization of cardiac myofilament is the absolute cause of the pathogenesis of dilated cardiomyopathy associated with this mutation and strongly suggest that Ca(2+) sensitizers are beneficial for the treatment of dilated cardiomyopathy patients affected by sarcomeric regulatory protein mutations.

Citing Articles

In silico and in vitro models reveal the molecular mechanisms of hypocontractility caused by M8R.

Creso J, Gokhan I, Rynkiewicz M, Lehman W, Moore J, Campbell S Front Physiol. 2024; 15:1452509.

PMID: 39282088 PMC: 11392859. DOI: 10.3389/fphys.2024.1452509.


Integrative proteomic and metabolomic elucidation of cardiomyopathy with in vivo and in vitro models and clinical samples.

Hu Y, Zou Y, Qiao L, Lin L Mol Ther. 2024; 32(10):3288-3312.

PMID: 39233439 PMC: 11489546. DOI: 10.1016/j.ymthe.2024.08.030.


Reinforcement of pimobendan with guideline-directed medical therapy may reduce the rehospitalization rates in patients with heart failure: retrospective cohort study.

Iwade Y, Kubota Y, Hayashi D, Nishino T, Watanabe Y, Kato K J Pharm Health Care Sci. 2024; 10(1):24.

PMID: 38769584 PMC: 11103862. DOI: 10.1186/s40780-024-00346-w.


Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin T.

Greenberg L, Stump W, Lin Z, Bredemeyer A, Blackwell T, Han X bioRxiv. 2024; .

PMID: 38645235 PMC: 11030379. DOI: 10.1101/2024.04.05.588306.


Altering Calcium Sensitivity in Heart Failure: A Crossroads of Disease Etiology and Therapeutic Innovation.

Saad N, Mashali M, Repas S, Janssen P Int J Mol Sci. 2023; 24(24).

PMID: 38139404 PMC: 10744146. DOI: 10.3390/ijms242417577.